个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Antitumor activity and safety profile of trilaciclib in Chinese patients with extensive-stage small cell lung cancer (ESSCLC) receiving chemotherapy (TRACES): Updated results from TRACES

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Liu, Y.[1] ; Wu, L.[2] ; Huang, D.[3] ; Wang, Q.[4,5] ; Fan, Y.[6] ; Liu, Z.[7] ; Fan, H.[8] ; Yao, W.[9] ; Liu, B.[10] ; Yu, G.[11] ; Pan, Y.[12] ; Xu, F.[13] ; He, Z.[14,15] ; Dong, X.[16] ; Ma, R.[17] ; Min, X.[18] ; Ge, X.[19] ; Chen, H.[20] ; Liu, Q.[21] ; Cheng, Y.[1] ;
机构： [1]Jilin Canc Hosp, Thorac Oncol Dept, Changchun, Peoples R China [2]Hunan Canc Hosp, Dept Thorac Med Oncol, Changsha, Peoples R China [3]TMUCIH Tianjin Med UnivCanc Inst & Hosp, Dept Pulm Oncol, Tianjin, Peoples R China [4]Zhengzhou Univ, Resp Dept, Ward 3, Affiliated Canc Hosp, Zhengzhou, Peoples R China [5]Henan Canc Hosp, Zhengzhou, Peoples R China [6]Zhejiang Canc Hosp, Dept Thorac Med Oncol, Canc Res Inst, Hangzhou, Peoples R China [7]Shandong Canc Hosp & Inst, Resp Dept, Ward 3, Jinan, Peoples R China [8]Zhengzhou Univ, Dept Thorac Med Oncol, Affiliated Hosp 1, Zhengzhou, Peoples R China [9]UESTC, Dept Thorac Med Oncol, Affiliated Canc Hosp, Sch Med,Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [10]Harbin Med Univ, Resp Dept, Ward 1, Canc Hosp, Harbin, Peoples R China [11]Weifang People Hosp, Dept Oncol, Weifang, Peoples R China [12]Anhui Prov Hosp, Dept Oncol, Hefei, Anhui, Peoples R China [13]Nanchang Univ, Dept Resp & crit care Med, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China [14]Fujian Canc Hosp, Dept Thorac Oncol, Div 25, Fuzhou, Peoples R China [15]Fujian Med Univ, Canc Hosp, Fuzhou, Peoples R China [16]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept thorac Oncol,Canc Ctr, Wuhan, Peoples R China [17]Liaoning Canc Hosp & Inst, Med Oncol, Shenyang, Peoples R China [18]Anhui Chest Hosp, Tumor radiotherapy Dept, Hefei, Peoples R China [19]Jiangnan Univ, Dept Oncol, Affiliated Hosp, Wuxi, Peoples R China [20]Guangdong Med Coll, Oncol Ctr Dist 1, Affiliated Hosp, Zhanjiang, Guangdong, Peoples R China [21]Xiamen Univ, Detp Resp & crit care Med, Affiliated Hosp 1, Xiamen, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.09.1229
ISSN：
基金：
Nanjing Zaiming Pharmaceutical Co., Ltd.
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Jilin Canc Hosp, Thorac Oncol Dept, Changchun, Peoples R China
推荐引用方式(GB/T 7714)：
Liu Y.,Wu L.,Huang D.,et al.Antitumor activity and safety profile of trilaciclib in Chinese patients with extensive-stage small cell lung cancer (ESSCLC) receiving chemotherapy (TRACES): Updated results from TRACES[J].ANNALS OF ONCOLOGY.2023,34:S1066-S1066.doi:10.1016/j.annonc.2023.09.1229.
APA：
Liu, Y.,Wu, L.,Huang, D.,Wang, Q.,Fan, Y....&Cheng, Y..(2023).Antitumor activity and safety profile of trilaciclib in Chinese patients with extensive-stage small cell lung cancer (ESSCLC) receiving chemotherapy (TRACES): Updated results from TRACES.ANNALS OF ONCOLOGY,34,
MLA：
Liu, Y.,et al."Antitumor activity and safety profile of trilaciclib in Chinese patients with extensive-stage small cell lung cancer (ESSCLC) receiving chemotherapy (TRACES): Updated results from TRACES".ANNALS OF ONCOLOGY 34.(2023):S1066-S1066

资源点击量：43390 今日访问量：1 总访问量：3121 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号